Literature DB >> 21577110

Clinical application of molecular pathology in sarcomas.

Salvatore Romeo1, Angelo P Dei Tos.   

Abstract

PURPOSE OF REVIEW: This review is intended to highlight the clinical application of molecular pathology as a tool for diagnostic accuracy and prognostic and predictive use and finally to discover novel molecular therapeutic targets. RECENT
FINDINGS: We are living an exciting era in sarcomas' therapy. This is the result of overcoming two crucial obstacles: lack of effective and specific drugs; lack of specific therapeutic regimen for distinct clinical entities. As new specific drugs have become available, it has become clear that an accurate diagnosis is the prerequisite for a specific therapy. This approach has been successfully applied to gastrointestinal stromal tumor and is now also being used in other sarcomas. The more recent findings are hereby reviewed.
SUMMARY: The inclusion of the molecular pathology in the diagnostic surgical pathology is instrumental for the application of molecularly tailored therapy. However, the degree of complexity of this approach requires additional caution in the data interpretation and in the reproducibility of the results. As molecular knowledge is improving and more sophisticated and powerful techniques are going to be routinely used, the success rate in treating sarcomas is expected to significantly increase.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21577110     DOI: 10.1097/CCO.0b013e328347b9be

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  4 in total

1.  Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.

Authors:  Daniel Braas; Ethan Ahler; Brenna Tam; David Nathanson; Mirielle Riedinger; Matthias R Benz; Kathleen B Smith; Fritz C Eilber; Owen N Witte; William D Tap; Hong Wu; Heather R Christofk
Journal:  Cancer Discov       Date:  2012-12       Impact factor: 39.397

2.  Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups.

Authors:  Martin Benesch; André O von Bueren; Tobias Dantonello; Katja von Hoff; Torsten Pietsch; Ivo Leuschner; Alexander Claviez; Uta Bierbach; Gabriele Kropshofer; Rudolf Korinthenberg; Norbert Graf; Meinolf Suttorp; Rolf Dieter Kortmann; Carsten Friedrich; Nicolas von der Weid; Peter Kaatsch; Thomas Klingebiel; Ewa Koscielniak; Stefan Rutkowski
Journal:  J Neurooncol       Date:  2012-12-11       Impact factor: 4.130

3.  Genetic polymorphisms of interleukin-1 beta and osteosarcoma risk.

Authors:  Yu He; XinJun Liang; ChunQing Meng; ZengWu Shao; Yong Gao; Qiang Wu; JianXiang Liu; Hong Wang; ShuHua Yang
Journal:  Int Orthop       Date:  2014-05-31       Impact factor: 3.075

4.  The off-label use of targeted therapies in sarcomas: the OUTC'S program.

Authors:  Lauriane Eberst; Claire Cropet; Axel Le Cesne; Patricia Pautier; Nicolas Penel; Antoine Adenis; Christine Chevreau; Jacques-Olivier Bay; Olivier Collard; Didier Cupissol; Florence Duffaud; Jean-Claude Gentet; Sophie Piperno-Neumann; Perrine Marec-Berard; Emmanuelle Bompas; Antoine Thyss; Loic Chaigneau; Philippe Cassier; François Bertucci; Jean-Yves Blay; Isabelle Ray-Coquard
Journal:  BMC Cancer       Date:  2014-11-24       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.